Sarepta Therapeutics Inc. (SRPT) Raised to Outperform at RBC Capital Markets
A number of other equities analysts have also recently issued reports on the company. Royal Bank Of Canada upgraded Sarepta Therapeutics from a sector perform rating to an outperform rating and set a $83.00 price objective for the company in a report on Monday. Leerink Swann restated an underperform rating and set a $5.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, August 4th. Vetr cut Sarepta Therapeutics from a hold rating to a sell rating and set a $17.28 price objective for the company. in a report on Monday, May 23rd. Robert W. Baird restated an outperform rating and set a $23.00 price objective on shares of Sarepta Therapeutics in a report on Monday, July 18th. Finally, Oppenheimer Holdings Inc. restated an outperform rating and set a $60.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday, July 26th. Two analysts have rated the stock with a sell rating, four have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. Sarepta Therapeutics has a consensus rating of Buy and an average target price of $51.01.
Sarepta Therapeutics (NASDAQ:SRPT) opened at 56.22 on Monday. Sarepta Therapeutics has a one year low of $8.00 and a one year high of $58.87. The stock’s 50 day moving average price is $29.05 and its 200 day moving average price is $21.62. The company’s market capitalization is $2.69 billion.
Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.19) by $0.16. During the same quarter in the previous year, the company earned ($0.87) earnings per share. Equities analysts anticipate that Sarepta Therapeutics will post ($4.17) EPS for the current fiscal year.
In other news, VP Jayant Aphale sold 35,000 shares of the stock in a transaction dated Monday, September 19th. The stock was sold at an average price of $50.00, for a total value of $1,750,000.00. Following the transaction, the vice president now directly owns 21,490 shares of the company’s stock, valued at $1,074,500. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Edward M. Md Kaye sold 24,557 shares of the stock in a transaction dated Wednesday, September 14th. The shares were sold at an average price of $30.00, for a total value of $736,710.00. Following the completion of the transaction, the chief executive officer now directly owns 76,983 shares in the company, valued at $2,309,490. The disclosure for this sale can be found here. 10.90% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in SRPT. American Century Companies Inc. purchased a new position in shares of Sarepta Therapeutics during the second quarter worth $651,000. Eagle Asset Management Inc. purchased a new position in shares of Sarepta Therapeutics during the second quarter worth $6,756,000. Amici Capital LLC purchased a new position in shares of Sarepta Therapeutics during the first quarter worth $488,000. LGL Partners LLC raised its position in shares of Sarepta Therapeutics by 4.2% in the first quarter. LGL Partners LLC now owns 24,862 shares of the company’s stock worth $485,000 after buying an additional 1,000 shares in the last quarter. Finally, A.R.T. Advisors LLC purchased a new position in shares of Sarepta Therapeutics during the first quarter worth $7,461,000. 72.09% of the stock is currently owned by institutional investors and hedge funds.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.